Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alprazolam + valproate is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Alprazolam is a benzodiazepine that acts as a central nervous system depressant by binding to γ-aminobutyric acid (GABA) type-A receptors in the brain, enhancing their inhibitory effect on neurotransmission. It is primarily used for the treatment of anxiety disorders and panic disorder[3][9][10]. Valproate (valproic acid or its salt forms such as valproate sodium) is an anticonvulsant and mood stabilizer that increases brain concentrations of gamma-aminobutyric acid (GABA), thereby exerting antiepileptic, antimigraine, and mood-stabilizing effects[4][6][8]. The combination may be considered in clinical scenarios where both anxiolytic/sedative effects (from alprazolam) and anticonvulsant/mood stabilization (from valproate) are desired; however, this combination carries an increased risk for central nervous system depression due to pharmacokinetic interactions—valproic acid can decrease the metabolism of alprazolam leading to higher blood levels and increased side effects[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam + valproate.